Brief: Graphite Bio Doses First Patient With Investigational Gene Editing Therapy Gph101 For Sickle Cell Disease

LENZ Therapeutics

11/08/2022 15:19

Aug 11 (Reuters) - Graphite Bio Inc  GRPH.O :
    * GRAPHITE BIO DOSES FIRST PATIENT WITH INVESTIGATIONAL GENE
EDITING THERAPY GPH101 FOR SICKLE CELL DISEASE
    * GRAPHITE BIO INC- INITIAL PROOF-OF-CONCEPT DATA FROM PHASE
1/2
CEDAR TRIAL ANTICIPATED IN MID-2023

Further company coverage:  GRPH.O 

 ((reuters.briefs@thomsonreuters.com;))